ALXN News and Press, Alexion Pharmaceuticals Inc. From 11/04/20

- Accepted abstracts include Phase 2 safety, efficacy, and tolerability data for CAEL-101 in AL amyloidosis - - Phase 3 studies of CAEL-101 in AL amyloidosis are underway - Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced...

- Six abstracts accepted, including new data from Phase 3 clinical trial extension studies demonstrating the safety and efficacy of ULTOMIRIS ® (ravulizumab-cwvz) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in older patients, those with and without a histor...

Image source: The Motley Fool. Alexion Pharmaceuticals (NASDAQ: ALXN) Q3 2020 Earnings Call Oct 29, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Alexion Pharmaceuticals (ALXN) Q3 2020 Earnings Call Transcript

Investors might not be overly excited about Alexion Pharmaceutical 's (NASDAQ: ALXN) stock performance so far in 2020. But with shares trading at only 10 times expected earnings, Alexion is arguably one of the biggest bargains in all of biotech . Alexion might not be such a ...

Alexion Pharmaceuticals, Inc. (ALXN) Q3 2020 Earnings Conference Call October 29, 2020 8:00 AM ET Company Participants Chris Stevo – Head-Investor Relations Ludwig Hantson – Chief Executive Officer Aradhana Sarin – Chief Financial Officer John Orloff – Global Head-...

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Alexion Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation

Alexion Pharmaceuticals (ALXN) Q3 results:Revenues: $1,588.7M (+25.8%); product sales: $1,588.3M (+25.7%).Key product sales: Soliris: $1,042.3 (+5.2%); Ultomiris: $289.3M (+221.8%); Strensiq: $189.4M (+22.7%); Andexxa: $38.9M; Kanuma: $28.4M (flat).Net income: $578.1M (+23.6%); non-GAAP net i...

Alexion Pharmaceuticals (ALXN): Q3 Non-GAAP EPS of $3.24 beats by $0.64; GAAP EPS of $2.62 beats by $0.59.Revenue of $1.59B (+26.2% Y/Y) beats by $160M.Shares +3.05% PM.Press Release For further details see: Alexion Pharmaceuticals EPS beats by $0.64, beats on revenue

3Q20 total revenues of $1,588.7 million, a 26% increase over 3Q19 3Q20 GAAP diluted EPS of $2.62; non-GAAP diluted EPS of $3.24 Received Japanese approval for ULTOMIRIS ® (ravulizumab) in atypical hemolytic uremic syndrome (aHUS) Received U.S. approval...

Alexion Pharmaceuticals (NASDAQ:ALXN) is scheduled to announce Q3 earnings results on Thursday, October 29th, before market open.The consensus EPS Estimate is $2.60 (-6.8% Y/Y) and the consensus Revenue Estimate is $1.43B (+13.5% Y/Y).Estimated Expenses on a non-GAAP basis R&D $268.6M and...